Next Article in Journal
Sickle Cell Disease: Metabolomic Profiles of Vaso-Occlusive Crisis in Plasma and Erythrocytes
Previous Article in Journal
Long-Term Redistribution of Peripheral Lymphocyte Subpopulations after Switching from Calcineurin to mTOR Inhibitors in Kidney Transplant Recipients
Review

The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia

1
Department of Diabetes, Endocrinology and Metabolism, The Royal North Shore Hospital, University of Sydney, Reserve Road, St Leonards NSW 2065, Australia
2
Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne VIC 3004, Australia
3
Ipswich Hospital, University of Queensland, Chelmsford Avenue, Ipswich QLD 4305, Australia
4
Mater Hospital Brisbane, Raymond Terrace, South Brisbane QLD 4101, Australia
5
Launceston Diabetes Clinic, 247 Wellington Street, Launceston TAS 7250, Australia
6
Department of General Practice and Primary Health Care, University of Melbourne, 230 Gratton Street, Parkville VIC 3010, Australia
7
Department of Endocrinology & Diabetes, St Vincent’s Hospital Melbourne, University of Melbourne, 41 Victoria Parade, Fitzroy VIC 3065, Australia
8
Diabetes Centre, Royal Prince Alfred Hospital, Sydney NSW 2050, Australia
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(4), 1091; https://doi.org/10.3390/jcm9041091
Received: 25 March 2020 / Accepted: 8 April 2020 / Published: 11 April 2020
(This article belongs to the Section Endocrinology & Metabolism)
Treatment intensification in people with type 2 diabetes following failure of basal insulin commonly involves the addition of a rapid-acting insulin analogue (basal plus one or more prandial doses; multiple daily injections) or by a switch to premixed insulin. Insulin degludec/insulin aspart (IDegAsp), comprising rapid-acting insulin aspart and ultra-long-acting insulin degludec in solution, enables both fasting and post-prandial glucose control, with some advantages over other treatment intensification options. These include straightforward dose titration, flexibility in dose timing, low injection burden, simplicity of switching and a lower risk of hypoglycaemia. In Australia, where insulin degludec on its own is not available, IDegAsp enables patients to still benefit from its ultra-long-acting properties. This review aims to provide guidance on where and how to use IDegAsp. Specifically, guidance is included on the initiation of IDegAsp in insulin-naïve patients, treatment intensification from basal insulin, switching from premixed or basal-bolus insulin to IDegAsp, up-titration from once- to twice-daily IDegAsp and the use of IDegAsp in special populations or situations. View Full-Text
Keywords: insulin degludec/insulin aspart; IDegAsp; co-formulation; type 2 diabetes; Australia insulin degludec/insulin aspart; IDegAsp; co-formulation; type 2 diabetes; Australia
Show Figures

Figure 1

MDPI and ACS Style

Glastras, S.J.; Cohen, N.; Dover, T.; Kilov, G.; MacIsaac, R.J.; McGill, M.; Fulcher, G.R. The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia. J. Clin. Med. 2020, 9, 1091. https://doi.org/10.3390/jcm9041091

AMA Style

Glastras SJ, Cohen N, Dover T, Kilov G, MacIsaac RJ, McGill M, Fulcher GR. The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia. Journal of Clinical Medicine. 2020; 9(4):1091. https://doi.org/10.3390/jcm9041091

Chicago/Turabian Style

Glastras, Sarah J., Neale Cohen, Thomas Dover, Gary Kilov, Richard J. MacIsaac, Margaret McGill, and Greg R. Fulcher. 2020. "The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia" Journal of Clinical Medicine 9, no. 4: 1091. https://doi.org/10.3390/jcm9041091

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop